RNA Therapeutics Part B

RNA therapeutics,Part B,Volume 204 covers a new class of medication based on RNA molecules,with chapters on various topics such as cardiovascular disorders, kidney injury, beta-thalassemia, infectious diseases, reproductive diseases, drug repurposing, glioma/glioblastoma, regenerative medicine, and liposome-based and polymeric nanoparticulate delivery systems for cancer.

Format: Hardback
Length: 358 pages
Publication date: 12 March 2024
Publisher: Elsevier Science Publishing Co Inc

RNA Therapeutics, Part B, Volume 204, is a comprehensive resource that provides up-to-date information on a novel class of medications derived from RNA molecules. The book encompasses a wide range of topics, including the use of RNA therapeutics for cardiovascular disorders, kidney injury, beta-thalassemia, infectious diseases, reproductive diseases, drug repurposing for various diseases, glioma/glioblastoma, regenerative medicine, liposome-based delivery systems for RNA therapeutics in cancer, and polymeric nanoparticulate delivery systems for RNA therapeutics in cancer.

The use of RNA therapeutics for cardiovascular disorders is explored in detail, with chapters covering the development of RNA-based therapies for heart failure, myocardial infarction, and stroke. These therapies aim to target specific genetic mutations or pathways involved in these diseases, offering potential new treatments for patients with these conditions.

RNA therapeutics for kidney injury are also discussed, highlighting the potential of RNA-based therapies to repair damaged kidney tissue and improve kidney function. These therapies are being developed to treat conditions such as chronic kidney disease and acute kidney injury, which have significant impacts on patient quality of life.

Beta-thalassemia is another condition that is being targeted by RNA therapeutics, with chapters discussing the development of RNA-based therapies to correct the genetic defect that causes this disease. These therapies have the potential to improve patient outcomes and reduce the need for blood transfusions and bone marrow transplants.

Infectious diseases are another area where RNA therapeutics are being developed, with chapters covering the use of RNA-based therapies for the treatment of HIV, COVID-19, and other infectious diseases. These therapies aim to target the virus or the immune response involved in these diseases, offering potential new treatments for patients with these conditions.

Reproductive diseases are also covered in the book, with chapters discussing the use of RNA-based therapies for the treatment of infertility, pregnancy complications, and other reproductive disorders. These therapies aim to target specific genetic mutations or pathways involved in these diseases, offering potential new treatments for patients with these conditions.

Drug repurposing is another area where RNA therapeutics are being explored, with chapters discussing the potential of RNA-based therapies to treat other diseases. This approach involves using existing medications to target new diseases or conditions, offering potential new treatments for patients with these conditions.

Glioma/glioblastoma is a type of brain cancer that is being targeted by RNA therapeutics, with chapters discussing the development of RNA-based therapies to treat this disease. These therapies aim to target specific genetic mutations or pathways involved in this disease, offering potential new treatments for patients with this condition.

Regenerative medicine is another area where RNA therapeutics are being developed, with chapters discussing the use of RNA-based therapies to repair damaged tissue and promote healing. These therapies are being developed to treat conditions such as spinal cord injury, diabetes, and other diseases that involve tissue damage.

Liposome-based delivery systems for RNA therapeutics in cancer are also discussed, highlighting the potential of these systems to improve the delivery of RNA-based therapies to cancer cells. These systems aim to increase the effectiveness of RNA-based therapies while reducing the side effects associated with traditional cancer treatments.

Polymeric nanoparticulate delivery systems for RNA therapeutics in cancer are also discussed, highlighting the potential of these systems to improve the delivery of RNA-based therapies to cancer cells. These systems aim to increase the effectiveness of RNA-based therapies while reducing the side effects associated with traditional cancer treatments.

Overall, RNA Therapeutics, Part B, Volume 204 is a valuable resource for researchers, physicians, and healthcare professionals interested in the development and application of RNA-based therapies. The book provides up-to-date information on a wide range of topics, including the potential of RNA and transcriptomic data to drive drug repurposing for various diseases. The book also highlights the advances in liposome-based delivery systems for RNA therapeutics in cancer and polymeric nanoparticulate delivery systems for RNA therapeutics in cancer, which are critical for the effective delivery of RNA-based therapies to cancer cells.

Weight: 450g
Dimension: 229 x 151 (mm)
ISBN-13: 9780443235443